 |
|
[Alpha Biz=(Chicago) Reporter Kim Jisun] KoBioLabs announced on June 6 that it will terminate the technology transfer contract for microbiome new drug candidate materials with Kolmar Holdings Korea.
"We decided to terminate the technology transfer contract for KBL382 and KBL1027, two new drug candidates for immune diseases signed with Kolmar Holding Korea on Nov. 30, 2020," the company said. "We will not return the deposit (2 billion won) received and have all rights to additional non-clinical research, production and development data conducted by Kolmar Holding Korea."
"This was decided by mutually reflecting our intention to promote the change in the internal business strategy of Kolmar Holdings Korea and the rapid development of KBL382, which is rich in market potential," the company said. "We are establishing our own development plan for the new drug candidate."
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
